{
    "clinical_study": {
        "@rank": "168309", 
        "arm_group": [
            {
                "arm_group_label": "ASG-22CE Dose Level 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASG-22CE Dose Level 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASG-22CE Dose Level 3", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASG-22CE Dose Level 4", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and pharmacokinetics ASG-22CE as well as\n      assess the immunogenicity and antitumor activity in subjects with metastatic urothelial\n      cancer."
        }, 
        "brief_title": "A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer That Express Nectin-4", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Urothelial Cancer", 
        "detailed_description": {
            "textblock": "All subjects will receive a single 30 minute IV infusion of ASG-22CE once weekly for 3 weeks\n      of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 4 weeks. The study design will\n      follow a modified Continual Reassessment Method (mCRM).\n\n      Subjects will continue treatment until disease progression, intolerability of ASG-22CE,\n      investigator decision or consent withdrawal. Subjects will have a Safety Follow up Visit a\n      minimum of 28 days after the last ASG-22CE infusion.\n\n      A data review team (DRT) will review cumulative unaudited data on an interim basis to\n      explore additional doses and/or schedules, or the expansion of existing cohorts. Doses\n      intermediate to those predefined in the protocol may be explored with DRT endorsement."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed metastatic transitional cell carcinoma of the urothelium\n             (TCCU) (i.e., cancer of the bladder, renal pelvis, ureter, or urethra)\n\n          -  Subjects must have a tumor positive (Immunohistochemical (IHC) H-score \u2265150) for\n             Nectin-4 expression (as measured by central laboratory using primary or metastatic\n             tumor tissue)\n\n          -  Must have failed at least one prior chemotherapy regimen for metastatic disease\n             and/or is unfit for cisplatin-based chemotherapy\n\n          -  Subjects must have measurable disease according to RECIST (version 1.1)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Life expectancy of \u2265 3 months\n\n          -  Negative pregnancy test (women of childbearing potential)\n\n          -  Hematologic function, as follows (no red blood cell or platelet transfusions are\n             allowed within 14 days of the first dose of ASG-22CE):\n\n               -  Absolute neutrophil count (ANC) \u2265 1.0 x 10 9/L\n\n               -  Platelet count \u2265 100 x 10 9/L\n\n               -  Hemoglobin \u2265 9 g/dL\n\n          -  Renal function, as follows: serum creatinine \u2264 2.0 mg/dL, or measured 24 hour\n             creatinine clearance of \u2265 45 mL/min\n\n          -  Total bilirubin < 1.5 x ULN (upper limit of normal)\n\n          -  Serum albumin > 2.5 g/dL\n\n          -  Aspartate aminotransferase (AST) \u2264 1.5 x ULN\n\n          -  Alanine aminotransferase (ALT) \u2264 1.5 x ULN\n\n          -  Gamma-glutamyl transpeptidase (Gamma GT) \u2264 1.5 x ULN\n\n          -  International normal ratio (INR) < 1.3 or \u2264 institutional ULN (or \u2264 3.0 if on\n             therapeutic anticoagulation)\n\n          -  Sexually active fertile subjects, and their partners, must agree to use medically\n             accepted double-barrier methods of contraception (e.g., barrier methods, including\n             male condom, female condom, or diaphragm with spermicidal gel) during the study and\n             at least 6 weeks after termination of study therapy\n\n          -  Competent to comprehend, sign, and date an independent ethics committee/institutional\n             review board/research ethics board (IEC/IRB/REB) approved informed consent form\n\n        Exclusion Criteria:\n\n          -  Preexisting sensory neuropathy Grade \u2265 2\n\n          -  Preexisting motor neuropathy Grade \u2265 2\n\n          -  Uncontrolled central nervous system metastases\n\n          -  Use of any investigational drug within 14 days or 5 half-lives prior to the first\n             dose of study drug\n\n          -  Any anticancer therapy within 14 days prior to the first dose of study drug,\n             including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy,\n             radiotherapy or any other agents to treat cancer (anti-hormonal therapy given as\n             adjuvant therapy for early-stage estrogen receptor (ER) positive breast cancer is not\n             considered cancer therapy for the purpose of this protocol)\n\n          -  Any P-glycoprotein (P-gp) inducers/inhibitors or strong cytochrome P4503A (CYP3A)\n             inhibitors within 14 days prior to the first dose of study drug\n\n          -  History of thromboembolic events and/or bleeding disorders \u2264 3 months (e.g., deep\n             vein thrombosis (DVT)  or pulmonary embolism (PE)) prior to the first dose of study\n             drug\n\n          -  Active angina or Class III or IV Congestive Heart Failure (CHF)  (New York Heart\n             Association CHF Functional Classification System) or clinically significant cardiac\n             disease within 12 months of study enrollment, including myocardial infarction,\n             unstable angina, grade 2 or greater peripheral vascular disease, congestive heart\n             failure, uncontrolled hypertension, or arrhythmias not controlled by outpatient\n             medication\n\n          -  Known Human Immunodeficiency Virus (HIV) or Acquired Immune Deficiency Syndrome\n             (AIDS)\n\n          -  Positive Hepatitis B surface antigen test\n\n          -  Positive Hepatitis C antibody test\n\n          -  Decompensated liver disease as evidenced by clinically significant ascites refractory\n             to diuretic therapy, hepatic encephalopathy, or coagulopathy\n\n          -  Known sensitivity to any of the ingredients of the investigational product ASG-22CE\n\n          -  Major surgery within 28 days prior to first dose of study drug\n\n          -  History of a primary invasive malignancy not listed in the inclusion criteria, which\n             has not been in remission for at least 3 years. The following are exempt from the 3\n             year limit:\n\n               -  non-melanoma skin cancer;\n\n               -  adenocarcinoma of the prostate that has been surgically treated with a\n                  post-treatment Prostate Specific Antigen (PSA) that is undetectable;\n\n               -  cervical carcinoma in situ on biopsy or squamous intraepithelial lesion on Pap\n                  smear; and\n\n               -  definitively treated, stage I/II ER positive breast cancer\n\n          -  History of uncontrolled diabetes mellitus or diabetic neuropathy\n\n          -  Active infection requiring treatment \u22647 days before dose of study drug\n\n          -  History of eye surgery within 6 months, presence of cataracts or other ocular\n             disorders significantly affecting vision\n\n          -  Condition or situation which may put the subject at significant risk, may confound\n             the study results, or may interfere significantly with subject's participation in the\n             study\n\n          -  Any medical, psychiatric, addictive or other kind of disorder which compromises the\n             ability of the subject to give written informed consent and/or to comply with\n             procedures"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02091999", 
            "org_study_id": "ASG-22CE-13-2"
        }, 
        "intervention": {
            "arm_group_label": [
                "ASG-22CE Dose Level 1", 
                "ASG-22CE Dose Level 2", 
                "ASG-22CE Dose Level 3", 
                "ASG-22CE Dose Level 4"
            ], 
            "description": "intravenous (IV) infusion", 
            "intervention_name": "ASG-22CE", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Metastatic Urothelial Cancer", 
            "Pharmacokinetics of ASG-22CE", 
            "ASG-22CE", 
            "Nectin 4 protein, humans", 
            "Safety", 
            "Clinical Trial, Phase 1", 
            "ASG-22ME", 
            "AGS-22C3E"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520"
                    }, 
                    "name": "Yale University School of Medicine"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami / Sylvester Comprehensive Cancer Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center and Research Institute, Inc."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fairway", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66205"
                    }, 
                    "name": "University of Kansas Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "University of Michigan Health System"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Karmanos Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Seattle Cancer Care Alliance"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "University of Wisconsin Carbone Cancer Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T2N 4N2"
                    }, 
                    "name": "Tom Baker Cancer Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Princess Margaret Cancer Centre"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer That Express Nectin-4", 
        "overall_contact": {
            "email": "Clinical@Agensys.com", 
            "last_name": "Agensys Clinical Research and Development", 
            "phone": "424-280-5000"
        }, 
        "overall_official": {
            "affiliation": "Agensys, Inc.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 24 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE):  Concentration at the end of infusion (CEOI)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 of Cycle 1 and Days 1, 8, and 15 of Cycle 2 and Day 1 of subsequent cycles up to an average of 24 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Maximum observed concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 of Cycle 1 and Days 1, 8, and 15 of Cycle 2 and Day 1 of subsequent cycles up to an average of 24 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Trough concentration (Ctrough)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 of Cycle 1 and Days 1, 8, and 15 of Cycle 2 and Day 1 of subsequent cycles up to an average of 24 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE): Time to maximum concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 of Cycle 1 and Days 1, 8, and 15 of Cycle 2 and Day 1 of subsequent cycles up to an average of 24 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE):  Partial area under the serum concentration-time curve after first dose and as appropriate (AUC0-7)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 of Cycle 1 and Days 1, 8, and 15 of Cycle 2 and Day 1 of subsequent cycles up to an average of 24 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE):  Terminal or apparent terminal half-life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 of Cycle 1 and Days 1, 8, and 15 of Cycle 2 and Day 1 of subsequent cycles up to an average of 24 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE):  Systemic clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 of Cycle 1 and Days 1, 8, and 15 of Cycle 2 and Day 1 of subsequent cycles up to an average of 24 months"
            }, 
            {
                "measure": "Pharmacokinetic parameter for total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE):  Volume of distribution at steady state (Vss)", 
                "safety_issue": "No", 
                "time_frame": "Days 1-4, 8, 15-18 of Cycle 1 and Days 1, 8, and 15 of Cycle 2 and Day 1 of subsequent cycles up to an average of 24 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02091999"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of Anti-Drug Antibody (ADA)", 
                "safety_issue": "No", 
                "time_frame": "up to 24 months"
            }, 
            {
                "description": "Incidence of tumor response defined as either a complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version 1.1) that is confirmed \u2265 28 days later", 
                "measure": "Tumor response", 
                "safety_issue": "No", 
                "time_frame": "up to 24 months"
            }, 
            {
                "description": "Defined as the percentage of subjects who experience a best response of either CR or PR in that cohort.  CR and PR must be confirmed \u2265 28 days later.", 
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "up to 24 months"
            }, 
            {
                "description": "Defined as the percentage of subjects who experience a best response of CR, PR or stable disease (SD)", 
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "up to 24 months"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Seattle Genetics, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Agensys, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}